BR112022021179A2 - Sistema de liberação de fármaco para a liberação local de agentes terapêuticos e usos do mesmo - Google Patents

Sistema de liberação de fármaco para a liberação local de agentes terapêuticos e usos do mesmo

Info

Publication number
BR112022021179A2
BR112022021179A2 BR112022021179A BR112022021179A BR112022021179A2 BR 112022021179 A2 BR112022021179 A2 BR 112022021179A2 BR 112022021179 A BR112022021179 A BR 112022021179A BR 112022021179 A BR112022021179 A BR 112022021179A BR 112022021179 A2 BR112022021179 A2 BR 112022021179A2
Authority
BR
Brazil
Prior art keywords
therapeutic agents
drug delivery
delivery system
local
local delivery
Prior art date
Application number
BR112022021179A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhang Hao
Zhang Weijiang
Feng Lichun
Wu Guolong
Li Dafeng
Original Assignee
Coval Biopharma Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coval Biopharma Shanghai Co Ltd filed Critical Coval Biopharma Shanghai Co Ltd
Publication of BR112022021179A2 publication Critical patent/BR112022021179A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112022021179A 2020-07-15 2021-07-13 Sistema de liberação de fármaco para a liberação local de agentes terapêuticos e usos do mesmo BR112022021179A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020102115 2020-07-15
PCT/CN2021/105899 WO2022012492A1 (en) 2020-07-15 2021-07-13 Drug delivery system for locally delivering therapeutic agents and uses thereof

Publications (1)

Publication Number Publication Date
BR112022021179A2 true BR112022021179A2 (pt) 2023-02-23

Family

ID=79555042

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021179A BR112022021179A2 (pt) 2020-07-15 2021-07-13 Sistema de liberação de fármaco para a liberação local de agentes terapêuticos e usos do mesmo

Country Status (10)

Country Link
US (1) US20230256106A1 (cg-RX-API-DMAC7.html)
EP (1) EP4181963A4 (cg-RX-API-DMAC7.html)
JP (1) JP7870259B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230040957A (cg-RX-API-DMAC7.html)
CN (2) CN117838875B (cg-RX-API-DMAC7.html)
AU (1) AU2021310171A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179897A1 (cg-RX-API-DMAC7.html)
IL (1) IL297377A (cg-RX-API-DMAC7.html)
WO (1) WO2022012492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907353A (zh) * 2021-02-09 2022-08-16 明慧医药(杭州)有限公司 一种前药化合物及其制备方法和用途
KR20240027732A (ko) * 2021-07-20 2024-03-04 코발 바이오파마 (상하이) 컴퍼니 리미티드 외용 항염증 결합 화합물 약물 및 그 제조 방법과 응용
AU2022348759A1 (en) * 2021-09-16 2024-01-25 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally delivering therapeutic agents and uses thereof
WO2023155905A1 (zh) * 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 化合物及其用途
KR20250012423A (ko) * 2023-07-17 2025-01-24 차의과학대학교 산학협력단 금 나노입자 및 상환변환 나노입자로부터 형성된 일시적 광천공을 위한 나노복합체
WO2026002095A1 (en) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally controlled release of therapeutic agents and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
CN101921347B (zh) 2004-01-07 2014-07-30 生化学工业株式会社 透明质酸衍生物及含有其的药剂
WO2006122954A2 (en) * 2005-05-18 2006-11-23 Eurand Pharmaceuticals Limited Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
IE20060565A1 (en) * 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
US9789200B2 (en) * 2008-04-22 2017-10-17 Fidia Farmaceutici S.P.A. Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
CN101745119B (zh) * 2010-01-25 2012-07-25 中国药科大学 羧酸类药物-多糖偶联物及其制备方法与应用
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
CN104603156B (zh) * 2012-09-05 2016-10-26 中外制药株式会社 引入有氨基酸和甾基的透明质酸衍生物
KR101467076B1 (ko) * 2013-02-20 2014-12-02 성균관대학교산학협력단 히알루론산-메토트렉세이트 접합체를 포함하는 관절염 예방 또는 치료용 약학적 조성물 및 이의 제조방법
CN103751795B (zh) * 2013-05-20 2017-02-08 中国药科大学 透明质酸‑抗肿瘤药偶联物及复合纳米粒组合物的制备和应用
US10098962B2 (en) * 2013-07-10 2018-10-16 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
CN104491875A (zh) * 2014-12-22 2015-04-08 中国药科大学 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
CN107096036B (zh) * 2017-04-12 2020-01-14 武汉理工大学 一种pH敏感型透明质酸-多柔比星纳米前药的制备方法及其应用
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN108467439A (zh) * 2018-03-22 2018-08-31 盐城师范学院 一种水溶性紫杉醇抗癌药物的制备方法
JP2022510986A (ja) * 2018-12-12 2022-01-28 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ ヒアルロン酸およびエピガロカテキン-3-o-没食子酸のコンジュゲートおよびナノ粒子ならびにその使用
WO2021243467A1 (en) * 2020-06-05 2021-12-09 London Pharmaceuticals And Research Corporation Cannabinoid-hyaluronic acid bioconjugates

Also Published As

Publication number Publication date
CN117838875A (zh) 2024-04-09
CN115867319B (zh) 2024-01-02
CN117838875B (zh) 2025-01-24
CN115867319A (zh) 2023-03-28
JP2023533679A (ja) 2023-08-04
US20230256106A1 (en) 2023-08-17
CA3179897A1 (en) 2022-01-20
WO2022012492A1 (en) 2022-01-20
IL297377A (en) 2022-12-01
JP7870259B2 (ja) 2026-06-04
EP4181963A1 (en) 2023-05-24
AU2021310171A1 (en) 2022-11-10
KR20230040957A (ko) 2023-03-23
EP4181963A4 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
MX2025014988A (es) Nuevas variantes de interleucina-2 para el tratamiento de cancer
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
EA201992484A1 (ru) Системы доставки с замедленным высвобождением, содержащие бесследные линкеры
CO2019013020A2 (es) Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anticdh6
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MX2022001540A (es) Composiciones farmaceuticas y metodos para contrarrestar la cardiotoxicidad inducida por quimioterapia.
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
BR112012032282A2 (pt) administração transdérmica de memantina
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
MX2016008138A (es) Sistema para el suministro transdermico de ingredientes activos.
MX2019011606A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX386251B (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
MX2019013893A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
BR112022012255A2 (pt) Formulações injetáveis de ação prolongada de sais de pamoato de cetamina
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
IL307997A (en) Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
EP3769751A4 (en) ULTRASONIC INDUCED DRUG DELIVERY SYSTEM WITH NANOBUBBLES DRUG CARRIER AND DRUG
MX2024010709A (es) Compuestos conjugados con ligando de cb1 y usos de estos
BR112016009749A8 (pt) hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide
BR112022012111A2 (pt) Sistema terapêutico transdérmico contendo agomelatina
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
EP4402152A4 (en) Drug delivery system for the local administration of therapeutic agents and its uses